All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
On December 14, 2020, the U.S. Food and Drug Administration (FDA) cleared the investigational new drug application for LB1901, an autologous chimeric antigen receptor (CAR) T-cell therapy that targets CD4, which is expressed in most T-cell lymphoma subtypes.
A first-in-human clinical trial of LB1901 will now be initiated in the U.S. for patients with relapsed/refractory peripheral T-cell lymphoma or cutaneous T-cell lymphoma. The primary objectives of the phase I study are to evaluate the safety and tolerability of LB1901 and to establish the recommended phase II dose.
This decision represents a positive step forward for patients with relapsed/refractory peripheral T-cell lymphoma or cutaneous T-cell lymphoma, for whom there is a significant unmet medical need.
Business Wire. Legend Biotech announces FDA clearance of the IND for LB1901, an investigational autologous anti-CD4 CAR-T therapy for relapsed or refractory T-cell lymphoma. https://www.businesswire.com/news/home/20201214005067/en/Legend-Biotech-Announces-FDA-Clearance-of-the-IND-for-LB1901-an-Investigational-Autologous-Anti-CD4-CAR-T-Therapy-for-Relapsed-or-Refractory-T-Cell-Lymphoma. Published Dec 14, 2020. Accessed Dec 18, 2020.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox